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	In the last decade, understanding of cancer initiation and progression has been given much attention with studies mainly focusing on genetic abnormalities. Importantly, cancer cells can influence their microenvironment and bi-directionally communicate with other systems such as the immune system. The nervous system plays a fundamental role in regulating immune responses to a range of disease states including cancer. Its dysfunction influences the progression of cancer. The role of the immune system in tumor progression is of relevance to the nervous system since they can bi-directionally communicate via neurotransmitters and neuropeptides, common receptors, and, cytokines. However, cross-talk between these cells is highly complex in nature, and numerous variations are possible according to the type of cancer involved. The neuro-immune interaction is essential in influencing cancer development and progression. 
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	Cancer is the major health related cause of death worldwide due to unhealthy lifestyle and other factors  ADDIN EN.CITE [1]. Although the mechanisms of cancer progression have been extensively studied in the last decades, these have been predominantly focused on cellular pathways of proto-oncogene, tumor suppressor gene mutations and mechanisms by which immune cells can eliminate cancer cells  ADDIN EN.CITE [2-5]. More recently, the impact of the tumor microenvironment in tumor cell invasion has attracted much interest [5, 6]. Multiple cellular and extracellular components within the tumor microenvironment, such as, immune cells, endothelial cells, mesenchymal stromal cells (fibroblasts and myofibroblasts), and their secretory products, exert active functions to modulate gene expression patterns of tumor cells which have an impact on their biological behavior  ADDIN EN.CITE [7-9]. Invariable crosstalk among these components within the tumor microenvironment triggers pro-survival, invasion and metastatic spread of tumor cells  ADDIN EN.CITE [10-13]. In addition, tumor cells interact with other cells to form organ-like structures that drive and promote cancer growth [3, 5]. The interaction between the tumor microenvironment and the complex immune system plays a major role in tumor progression and as a result, is of concern in cancer treatment [3]. However, it is only in recent years that the role of the neuro-immune network has surfaced as a major contributor to cancer progression. The mechanisms by which neuro-immune signaling in cancer influences its progression are not clear. 
	The nervous system plays a fundamental role in regulating immune responses to a range of disease states [14]. Its dysfunction influences the progression of disease outcomes including cancer cell growth. The role of the nervous system in tumor progression is of relevance to the immune system since they can bi-directionally communicate via neurotransmitters and neuropeptides, common receptors and cytokines  ADDIN EN.CITE [15, 16]. However, the crosstalk between these cells is highly complex in nature, and numerous variations are possible according to the type of cancer involved  ADDIN EN.CITE [17]. The interaction of the nervous system in modulating immune responses, innervation of lymphoid organs, affects various neurotransmitters influencing cancer. This review presents an overview of the neuro-immune interaction in cancer progression: lymphoid organs innervation; neurotransmitters and immune cells in cancer, tumor associated immune cells and the nervous system. 

2. Innervation of lymphoid organs
 
	The link between the nervous and immune systems is via direct innervation of lymphoid organs. In particular, sympathetic noradrenergic fibers innervate primary (thymus and bone marrow) and secondary (lymph nodes and spleen) lymphoid organs [18]. In lymphoid organs, the immune responses against pathogens or tissue damage are altered by the release of neuropeptides and neurotransmitters such as, neuropeptide Y, substance P (SP), norepinephrine and dopamine from nerve endings  ADDIN EN.CITE [18, 19]. Dysregulation of this interaction promotes pathogenesis and progression of many diseases including cancer [18]. The spleen plays an important role in response to pathogens or tissue damage; however, its response to cancer has been less empathized. In systemic inflammation, the vagal afferents activate the central nervous system (CNS) which triggers the efferent via the celiac ganglion and, as a result, activates immune cells in the spleen (as reviewed by Matteoli et al, 2013 [20]). As a consequence, the activation of adrenergic fibers innervating the spleen results in the release of norepinephrine leading to the activation of T cells secreting acetylcholine.
	The spleen accumulates monocytic and granulocytic precursors that directly replenish tumor-associated macrophages (TAMs) and neutrophils, as noted in lung adenocarcinoma  ADDIN EN.CITE [21, 22]. Moreover, the cords of the splenic subcapsule red pulp contain a reservoir of monocyte subsets (e.g. Ly-6Chigh and Ly-6Clow) that are promptly released in the bloodstream following acute injury [23]. Therefore, it can be speculated that the spleen would detect cancer as a pathogen and respond to it in a similar manner. However, cancer invades tissues without the spleen influencing it, in the same way as viruses invade target tissues by inactivating immune responses. In fact, stress or central inflammatory stimulation of the sympathetic nervous system (SNS) inhibits splenic macrophage function, thus, β-beta mechanisms influence splenic macrophages [24]. This supports the speculation that the spleen’s response to pathogens is via catecholamine release which acts on beta-adrenergic receptors to inhibit splenic macrophage activity. However, specific mechanisms of this action in cancer are not clear.
	Detailed neuro-anatomical description of lymph node (LN) innervation is scarce [18], however, sympathetic fibers in LNs have been reported [24]. In LNs, immune responses to antigens are initiated  ADDIN EN.CITE [24, 25]. During antigen detection, immune cells (dendritic cells (DCs), T cells, etc.) are recruited into regional LNs which activate immune responses against the antigen. The decision process within LNs to either induce an active immune response or be tolerant is not clear, although in most instances an active immune response is initiated  ADDIN EN.CITE [26-28]. Just like other foreign antigens, cancer cells can escape LN surveillance. It is suggested that the lack of LNs innervation may be a contributing factor to cancer escaping immune surveillance. Thus, information of LN innervation could aid in the understanding of the decision process within LNs to induce protective responses and its lack of response in cancer initiation. Furthermore, understanding the interaction between LN and cancer may aid therapeutic modalities at the early stages of disease.
	The SNS regulates bone marrow function [24]. Innervation within the bone marrow is also scarce and likely due to the fact that there is close contact with surrounding mineralized bone which receives sympathetic and sensory innervation [29].  However, sensory fibers containing SP and calcitonin gene-related peptide together with noradrenergic sympathetic fibers and veins are distributed throughout the bone marrow and surrounding bone. Distinguishing between innervated bone and bone marrow is not clear [18], even though, in rodents bone marrow innervation occurs late in fetal life, just prior to hemopoietic activity. Understanding innervation of the bone marrow will enhance our knowledge of bone marrow cancers including but not limited to, lymphoma, leukaemia, and myeloma. 

3. Neurotransmitters and immune cells in cancer

	Neurotransmitters play an essential role in the modulation of immunity. A number of immune cells such as, T cells, DCs, natural killer (NK) cells, microglia and myeloid-derived suppressor cells (MDSCs) express cell surface neurotransmitter receptors including substance P (SP), glutamategamma-aminobutyric acid (GABA), serotonin, dopamine, epinephrine, norepinephrine and acetylcholine (Table 1, Fig.1)  ADDIN EN.CITE [30-34].  Furthermore, studies have shown that various cancers express receptors for different neurotransmitters which play an essential role in the control of tumor progression  ADDIN EN.CITE [31, 32, 35-37].

3.1. Substance P 

	Substance P (SP) is expressed in both the central and peripheral nervous systems (PNS) and plays an essential role in the neuroimmune system crosstalk. Of the sensory neuropeptides, SP is distributed widely and regulates immune functions, including that of B and T cells [38] and cytokine secretion by monocytes  ADDIN EN.CITE [17] and macrophages. Binding of SP to its receptor NK1 triggers activation of intracellular pathways including cAMP, MEK, ERK1/2, mTOR and NF-kB resulting in proinflammatory cytokine production [39]. In addition, SP enhances lymphocyte proliferation and lymphokine-activated killer cell cytotoxicity, NK cell cytotoxicity, augments tumor necrosis factor alpha (TNF-alpha, interleukin (IL)-10 and IL-12 secretion by macrophages, and, decreases the number of tumor-infiltrating MDSCs  ADDIN EN.CITE [17]. The effects of chronic administration of low dose SP to the brain in a murine model of metastatic breast cancer co-treated with radiation treatment, increased the antigenicity of cancer cells [40]. Hence, SP through neuro-immune modulation can avert an immunosuppressive tumor microenvironment and consequently inhibiting metastatic growth.

3.2. Glutamatergic, GABAergic and serotonergic signaling. 

Glutamate is the principal excitatory neurotransmitter that regulates synaptic and cellular activity in the CNS via binding to its receptors including metabotropic glutamate receptors (mGluRs) or ionotropic glutamate receptors (iGluRs). In addition, glutamate also plays a fundamental role in the neuroimmune system crosstalk and it modulates immune cell functions via the expression of its functional receptors on immune cells  ADDIN EN.CITE [41]. Furthermore, immune cells such as T cells, DC, monocytes and macrophages release glutamate where they act in both an autocrine and paracrine fashion [42]. Although the role of glutamate and its receptors is well-established in neurological disorders and neuroprotection, it has become evident that glutamate plays a functional role in cancer via regulating immune cells as noted in head and neck, glioma, melanoma, gastric, prostate, squamous cell carcinoma, colorectal and breast cancers  ADDIN EN.CITE [32, 36, 37]. For instance, in head and neck cancer patients, elevated levels of glutamate increase spontaneous migration of peripheral T cells  ADDIN EN.CITE [32]. 
GABA is the main inhibitory neurotransmitter in the CNS. Nevertheless, GABA exerts physiologic effects in non-neuronal peripheral tissues and organs and via the activation of ionotropic (GABAA or GABAC) and metabotropic (GABAB) receptors [43]. GABA plays a functional role in the proliferation, migration and differentiation of cells including tumorigenic cells [44]. It has been noted that GABA mediates its inhibitory effect through GABAA receptor. For instance, GABA inhibits hepatocellular carcinoma cell migration through the activation of GABAA receptor [45]. In addition, administration of GABA agonist Nembutal suppresses tumor metastasis in colon cancer  ADDIN EN.CITE [46]. However, there are studies demonstrating that GABAA receptor enhances metastasis. The activation of GABAA receptors upregulates brain metastasis of breast cancer patients [47]. It is speculated that since GABA mediates it functional effect on T lymphocytes and DC through the activation of GABA-A [48], this may explain the inconsistency in findings. 









	SNS activation regulates an array of cancer-related molecular pathways by beta-adrenergic signaling and via beta-adrenergic receptors expressed by tumor cells, immune and vascular cells  ADDIN EN.CITE [57, 58]. beta-adrenergic receptors mediate a range of catecholamine effects on target cells and immune cells, as well as cancer cells, i.e. breast cancer cells  ADDIN EN.CITE [59-61];. Several cellular and molecular processes (such as inflammation, angiogenesis, epithelial mesenchymal transition and apoptosis) mediate beta-adrenergic influences on tumor progression [58] and recruitment of macrophages into primary tumors  ADDIN EN.CITE [62, 63]. Moreover, beta-adrenergic signaling influences the secretion of pro-inflammatory cytokines (IL-1, IL-6 and IL-8) by immune cells  ADDIN EN.CITE [62, 64-66], upregulation of vascular endothelial growth factor (VEGF) resulting in increased angiogenesis [67], matrix metalloproteinase (MMP) related increase of tissue invasion  ADDIN EN.CITE [67, 68], tumor cell assembly and motility  ADDIN EN.CITE [69, 70]. Furthermore, beta-adrenergic signaling suppresses CD8 T cell and NK cell responses  ADDIN EN.CITE [71] and inhibits the expression of type I interferons  ADDIN EN.CITE [63, 72]. In fact, in murine metastatic mammary adenocarcinoma, beta-adrenergic receptor agonist suppressed NK cell activity resulting in increased lung metastasis [73]. In addition, either stress or pharmacological beta-adrenergic stimulation results in increased macrophage infiltration and cancer metastasis which can be prevented by injection of a beta-adrenergic antagonist, propranolol [63]. Furthermore, the use of beta2-adrenergic agonist in experimental animals reverse muscle wasting (cachexia) associated with cancer  ADDIN EN.CITE [74]. Catecholamines can induce apoptosis of lymphocytes, alter the distribution of NK cells and suppress NK cell activity, which are all required for anti-tumor immunity  ADDIN EN.CITE [75], leading to tumor cell escape mechanisms. Thus, persistent release of neurotransmitters from nerve terminals may promote tumor growth and metastasis via modulation of the immune system. 
	
3.5. Cholinergic signaling 

	Modulation of the immune system by the sympathetic nervous system (SNS) has been extensively studied  ADDIN EN.CITE [20, 76, 77]. However, the role of the parasympathetic nervous system has gained attention only recently [78]. Inflammatory mediators can activate sensory nerves that send signals regarding inflammation to the CNS, which in turn leads to the release of neuromediators modulating local inflammation and influencing immune cells [79]. Consequently, the nervous system can regulate immune responses in peripheral tissues and restore local immune homeostasis [80]. Since inflammatory signals are important for tumor progression in both the early  and late  stages, the anti-inflammatory role of the vagus nerve may play an important role in tumorigenesis [81].
	It has been established that acetylcholine (ACh) acting on α7 nicotinic receptors (nAChRs) modulates splenic macrophages and inhibits TNF-alphaproduction in the spleen  ADDIN EN.CITE [82, 83]. In addition, vagus nerve activation stimulates ACh synthesis by splenic T lymphocytes leading to inhibition of cytokine production [83]. In lipopolysaccharide-induced inflammation in C56BL/6J mice, activation of 7 and 9 nAChRs expressed by bone marrow cells stimulates secretion of anti-inflammatory cytokines (IL-10 and transforming growth factor beta (TGF)-beta) and inhibits production of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-12) [30]. Similarly, secretion of TNF-alpha, IL-1beta, IL-6 and IL-18 induced by endotoxin was significantly inhibited by ACh and nicotine in human macrophage cultures [84]. ACh receptors including both muscarinic (mAChRs) and nAChRs are functionally expressed by cancer cells  ADDIN EN.CITE [85-87]. Moreover, cancer cells synthesize and secrete ACh [87]. In a mouse bearing B16 melanoma cells, administration of nicotine inhibits the release of cytokines and cell killing by NK cells via nAChR 2  ADDIN EN.CITE [31]. Overexpression of 7 nAChRs by cancer cells (i.e. human colon cancer cell line HT-29) promotes cancer angiogenesis  ADDIN EN.CITE [88, 89], cell proliferation and metastasis  ADDIN EN.CITE [90-94]. 9 nAChRs are reported to play a crucial role in breast cancer development; the correlation between expression levels of 9 nAChR mRNA and disease outcome was found in breast cancer patients  ADDIN EN.CITE [59]. On the other hand, it has been demonstrated that mAChRs antagonists inhibit small cell lung carcinoma growth both in vitro and in vivo via inhibiting MAPK pathway [87]. In BALB/c mice bearing LMM3 mammary adenocarcinoma cells, tumor macrophages express M1 and M2 mAChRs which trigger arginine metabolic pathway leading to tumor angiogenesis [95]. Understanding the principal mechanisms of cholinergic signaling in regulating the immune system may highlight the significance of ACh inhibitors in cancer therapy.

4. Tumor associated immune cells and the nervous system

	The role of nervous system in modulating tumor-associated immune (TAI) cells is not well understood. However, various TAI cells within tumor microenvironment play essential role in promoting tumor growth. It could be speculated that nervous system modulates TAI cells in its original form as normal immune cells.

4.1. Tumor-associated macrophages 

	Tumor associated macrophages (TAMs) play a role in beta-adrenergic signaling pathways, by accelerating angiogenesis, chemokine secretion to attract immune and tumor cells, secretion of pro-inflammatory cytokines (IL-1, IL-6, IL-8, and TNF-alpha) and escape of anti-tumor responses  ADDIN EN.CITE [96-98]. Hence, TAMs are sensitive to sympathetic signaling and raise the likelihood that stress-response pathways influence macrophage infiltration within the tumor microenvironment and, as a result, enhance metastasis. In the early or regression stages of tumors, TAMs, in particular, M1 macrophages (pro-inflammatory; releasing IL-1β, IL-6, IL-12, TNF-alpha, monocyte chemoattractant protein-1 (MCP-1)) inhibit angiogenesis and activate an anti-tumor immune response. In contrast, TAMs shift to a M2 phenotype (anti-inflammatory, releasing IL-1 receptor antagonist, TGF-beta, IL-4, IL-10, IL-13) which enhance tumor angiogenesis in advanced tumors  ADDIN EN.CITE [99-103], tumor growth [101], invasion, migration [104], metastatic spread  ADDIN EN.CITE [105] and possess immunosuppressive activities which are regulated by neuromediators [106]. In breast cancer, infiltrating TAMs correlate with higher tumor and vascular grade  ADDIN EN.CITE [61] and increased necrosis [107] leading to poor prognosis  ADDIN EN.CITE [61, 96, 108]. In fact, eliminating macrophages from the tumor site, either genetically or therapeutically, results in reduced tumor progression in breast cancer  ADDIN EN.CITE [61]. However, detailed understanding of the neuro-immune interaction influencing TAMs in human breast cancer needs further elucidation. 

4.2. Cancer-associated fibroblasts 

	The role of nervous system in modulating cancer associated fibroblasts (CAFs) remains scare. To understand how nervous system might modulate CAFs, studies need to understand the origin of CAFs. It is believe that CAFs originated from bone marrow-derived mesenchymal stem cells, fibroblasts or cancer cells that undergo endothelial - or epithelial -mesenchymal transition [109]. Therefore, it is possible that nervous system may regulate CAFs via modulating bone marrow-derived mesenchymal stem cells or fibroblasts. CAFs are the key constituent cells within the tumor microenvironment which interact with cancer cells promoting tumor growth and metastasis [110]. For example, in the tumor microenvironment of 4T1 metastatic breast cancer model, in vivo abolition of CAFs causes Th2 shift to Th1 polarization which is characterized by increased expression of IL-2 and IL-17, suppressed TAMs, T regulatory cells, MDSCs and decreased angiogenesis [111]. In addition, CAFs enhanced the aggressive phenotype of T47D, MCF-7 and MDA-MB-231 breast cancer cells via epithelial mesenchymal transition induced through paracrine TGF-beta signaling [112]. Similarly, in human sample of squamous cell carcinoma, CAFs mediate angiogenesis and inflammation via employing macrophages and stimulating angiogenesis, consequently enhancing tumor growth [113]. These findings demonstrate significant importance of CAFs in mediating tumor progression. Understanding the origin of CAFs could lead to better understanding of how nervous system modulates it, resulting in better therapies design.
  
4.3. Tumor-infiltrating lymphocytes 





Eosinophils release an array of cytokines, including IL-1beta, TNF-alpha, and interferon gamma and eosinophil derived neurotoxin that are potentially toxic to nerve cells. Eosinophils localize to nerves (eosinophil-nerve interaction) and are associated with enhanced nerve activity [121]. In addition, eosinophils infiltrate cancer cells leading to either favorable or unfavorable prognosis [122]. For instance, in Hodgkin’s lymphoma, eosinophils infiltration correlate with an unfavorable prognosis [123] whereas in colon cancer the presence of eosinophils leads to a favorable prognosis  ADDIN EN.CITE [124, 125]. However, the role of eosinophils and nerve interactions in cancer aetiology is not clear. The presence of eosinophils in necrotic regions of the tumor suggests that they may have anti-tumor effects associated with a favorable prognosis  ADDIN EN.CITE [126, 127]. Conversely, it has been noted that eosinophils may contribute to tumor invasion via activation of gelatinase  ADDIN EN.CITE [125, 126, 128, 129]. Furthermore, eosinophils at the tumor site can influence angiogenesis via VEGF secretion [130]. Moreover, TNF-alpha-stimulated eosinophils release pro-angiogenic factors such as, basic fibroblast growth factor, IL-6, IL-8, platelet-derived growth factor and MMP-9  ADDIN EN.CITE [128]. However, pro-angiogenic factors such as IL-15 and TNF-alpha-stimulated eosinophils have only been noted, and theirs role in tumors is not clear [13]. Secretion of eosinophilic granular proteins has been noted in breast cancer [131] and is associated with increased survival. However, Amini and colleagues reported lack of eosinophils in breast cancer [132] which warrants further research into eosinophil infiltration in breast cancer. 

4.5. Mucosal-associated invariant T (MAIT) cells
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Table 1. Modulation of immune cells by neurotransmitters
Neurotransmitter	Cancer type	Model	Function on immune cells	Ref.
Acetylcholine	Melanoma 	B16 melanoma cells in vitro and intravenous injection of B16 cells in C57BL/6 mice  	Nicotine inhibits NK cells capability to release cytokines and kill target cells via nAChR 2	 ADDIN EN.CITE [31]
Dopamine 	Lung cancer	Human patients,in vitro dopamine concentration	Plasma levels of dopamine is elevated in lung carcinoma patients Dopamine inhibits the cytotoxicity and proliferation of T cells via the activation of dopamine receptor 1 mediated by intracellular cAMP	 ADDIN EN.CITE [52]
		Human blood from lung cancer patients (stage I-IV); Lewis lung carcinoma and B16 melanoma cells in vitro and their subcutaneous injection in C57BL/6 mice  	Dopamine administration inhibits the suppressive function of Gr-1+ CD115+ MDSC on T cell proliferation via the activation of DR1 both in human blood in vitro and in vivo	 ADDIN EN.CITE [33]
	HNC	Human patients	Dopamine increases spontaneous migration of peripheral T cells in HNC patients	 ADDIN EN.CITE [32]
Epinephrine 	Leukemia 	CRNK-16 leukemia cells in vitro and intravenous injection of CRNK-16 cells in F344 rats 	Administration of epinephrine reduces NK activity. 	 ADDIN EN.CITE [71]
Glutamate 	HNC	Human patients	Glutamate increases spontaneous migration of peripheral T cells in HNC patients 	 ADDIN EN.CITE [32]
Norepinephrine 	Breast cancer	66c14 mammary adenocarcinoma cell injected into mammary fat pad of BALB/c mice	NE acts on β2-AR enhancing CD11b+F4/80+ macrophage and CD11b+ GrloLy6Chi myeloid-derived suppressor cell infiltration	[63]
Substance P	Breast cancer	4TBM cells in vitro and orthotopic injection of 4TBM cells in BALB/c mice 	SP increases CD4+CD25 cells in draining LNsPrevents tumor-induced degeneration of sensory nerve endingsAlters CAFs releasing of angiogenic factorsEnhances lymphokine-activated killer cell cytotoxicity, NK cell cytotoxicity, TNF-alpha, IL-10 and IL-12 secretion by macrophagesDecreases tumor-infiltrating myeloid-derived suppressor T cells 	 ADDIN EN.CITE [17]
DR1, dopamine receptor 1; NE, norepinephrine; SP, substance P; cAMP, cyclic adenosine monophosphate; nAChR, nicotinic acetylcholine receptor; IL-10, interleukin 10; IL-12, interleukin 12; CAFs, cancer associated fibroblasts; TNF-alpha, tumor necrosis factor-; NK, natural killer cells; LN, lymph node; beta2-AR, beta2-adrenergic receptor; HNC, head and neck cancer
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